Acquired Bruton's tyrosine kinase mutations in patients treated on the ibrutinib and rituximab, ibrutinib alone, and ibrutinib and venetoclax arms of the national multi-centre Phase III FLAIR study in previously untreated CLL patientsCharlotte Evans, Talha Munir, Sue Bell et al.|Blood|2025Cited by 2